证券记录 · 已归档季度
ARWR
Arrowhead Pharmaceuticals, Inc. · Healthcare · Biotechnology
16被追踪持有人
+2Δ持有人
54.75M持有股份
$865.08M报告持仓市值
+2新建仓位
−0清仓
动量输入(同类管理人):
持有人广度 +14.3% ·
股份流向 -0.7% ·
净新建仓位 +12.5%
· 公式
持有人分散化:持有人数增多,合计持仓比例缩小。
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q2 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 25.13K | $1.54M | n/a | n/a |
| Q2 2026 | 131 | +6 | 82.23M | $6.28B | +14 | −9 |
| Q1 2026 | 129 | +9 | 82.68M | $4.92B | +14 | −6 |
| Q4 2025 | 119 | +2 | 83.16M | $5.52B | +3 | n/a |
| Q3 2025 | 18 | 0 | 61.93M | $2.14B | +1 | −2 |
| Q2 2025 | 16 | +2 | 54.75M | $865.08M | +2 | n/a |
| Q1 2025 | 11 | +1 | 14.99M | $191.04M | +1 | n/a |
| Q4 2024 | 10 | -1 | 13.46M | $253.12M | +1 | −2 |
| Q3 2024 | 10 | +1 | 7.88M | $152.69M | +1 | n/a |
| Q2 2024 | 9 | n/a | 6.44M | $167.29M | n/a | n/a |
持有人 · Q2 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (被动) | 19.42M | n/a | $306.91M | 0.0% | n/c | 1 | SEC ↗ ×17 |
| 2 | The Vanguard Group ✦ (被动) | 15.53M | n/a | $245.30M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (被动) | 6.37M | -9.0% | $100.66M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Fidelity (FMR) ✦ | 5.17M | n/a | $81.69M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 5 | Geode Capital Management ✦ (被动) | 2.98M | +1.0% | $47.07M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | Marshall Wace ✦ | 2.16M | +3507.8% | $34.06M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 7 | Norges Bank ✦ (被动) | 1.92M | +6.8% | $30.41M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 8 | Fisher Asset Management ✦ | 451.65K | -6.5% | $7.14M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 9 | Millennium Management ✦ | 169.04K | -75.5% | $2.67M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 152.35K | +276.1% | $2.41M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 11 | Two Sigma Investments ✦ | 133.40K | -84.0% | $2.11M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 100.61K | +8.0% | $1.59M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 13 | Arrowstreet Capital ✦ | 64.20K | 新增 | $1.01M | 0.0% | New | 1 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 62.24K | -93.7% | $983,471 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 15 | Wellington Management ✦ | 48.28K | -8.2% | $762,902 | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
| 16 | Gotham Asset Management ✦ | 18.86K | 新增 | $298,035 | 0.0% | New | 1 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例,即持仓信心指标。✦ = 精选管理人。
新增买入方
| Arrowstreet Capital | $1.01M | 0.0% |
| Gotham Asset Management | $298,035 | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 430 持有人, 120.06M 股份, $7.40B 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券:基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Aug 18
OLUKOTUN ADEOYE Y
Director · 2.00K 股 · $173,920
Aug 18
PERRY MICHAEL S
Director · 11.60K 股 · $1.01M
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 14
SC 13G/A: Avoro Capital Advisors LLC
Jul 31
SC 13G/A: VANGUARD PORTFOLIO MANAGEMENT LLC
Jul 27
SC 13G/A: BlackRock, Inc.
数据来源: 持股数据来源于已解析的13F普通股持仓(被追踪范围,变动对比集);内部人行为来自Form 3/4/5;重大持股来自Schedule 13D/13G;所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2025 ·
方法论 ·
通过API获取此数据